Yahoo
NasdaqCM - BOATS Real Time Price USD

IceCure Medical Ltd (ICCM)

0.8701 -0.0583 (-6.28%)
At close: October 30 at 4:00:00 PM EDT
0.8983 +0.0282 (+3.24%)
Overnight: 8:27:57 PM EST
Chart Range Bar
Loading chart for ICCM
Chart does not reflect overnight price.
  • Previous Close 0.9284
  • Open 0.9400
  • Bid 1.2100 x 2000
  • Ask 1.4600 x 100
  • Day's Range 0.8201 - 0.9510
  • 52 Week Range 0.8200 - 23.4900
  • Volume 50,152
  • Avg. Volume 145,543
  • Market Cap (intraday) 4.036M
  • Beta (5Y Monthly) 0.43
  • PE Ratio (TTM) --
  • EPS (TTM) -6.8400
  • Earnings Date (est.) Nov 18, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 22.67
  • Zacks Rating Neutral

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.

www.icecure-medical.com

67

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ICCM
95.25%
S&P 500 (^GSPC)
10.73%

1-Year Return

ICCM
95.92%
S&P 500 (^GSPC)
11.11%

3-Year Return

ICCM
96.23%
S&P 500 (^GSPC)
81.91%

5-Year Return

ICCM
99.60%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 1.28M
Earnings -4.25M
Profit Margin -331.98%

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-4M
-3M
-2M
-1M
0
1M
-600.0%
-500.0%
-400.0%

Analyst Insights

View More

Analyst Price Targets

10.00
22.67 Average
0.8701 Current
30.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/14/2026
Analyst Maxim Group
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 3 -> 1

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -73.87%

  • Return on Equity (ttm)

    -228.31%

  • Revenue (ttm)

    3.95M

  • Net Income Avi to Common (ttm)

    -16.88M

  • Diluted EPS (ttm)

    -6.8400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    12.03M

  • Total Debt/Equity (mrq)

    0.76%

  • Levered Free Cash Flow (ttm)

    -9.54M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: